Monoclonal Antibodies Market to Witness Huge Growth by 2024: Key Players - Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co Inc., Amgen, Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and Co. and Mylan NV

Monoclonal Antibodies Market Overview:
Antibodies, which are proteins generated by plasma cells in response to specific antigens, are used for diagnostic and therapeutic purposes. Monoclonal antibodies (mAb), a type of monospecific antibody, are composed of identical antibody molecules and are produced by a single clone of cells or cell lines. Monoclonal antibodies have led to a fundamental change in the pharmaceutical and biotechnology sectors, and should also play a crucial role in the clinical protocol during the further development of these molecular agents. Monoclonal antibodies find application in the treatment of various diseases, including autoimmune, cancer and inflammatory diseases. The global monoclonal antibody market is characterized by the presence of many global and regional players and is dynamic in nature. Well-established players compete with local counterparts based on technology, costs and product differentiation. Given the promise of robust growth in the future, it is likely that more players will try to enter the market. However, strict guidelines regarding the manufacture of MAb can have a deterrent effect. It also provides a detailed analysis of opportunities and trends in the global market.

The report provides a detailed assessment of the dominant provider's outlook. It also presents the main market players and takes advantage of the most advanced analytical tools, and measures the threats and opportunities that these companies may face during the forecast period.

The Monoclonal Antibodies market was valued at USD xx billion in 2017 and is expected to reach USD xx billion by 2021 growing at a CAGR of xx% during the forecast period 2017 to 2021.

Avail Sample Brochure of the report @ https://www.researchcosmos.com/request/global-monoclonal-antibodies-market-report-industry-overvi/5911489

Drivers and restraints:
The increasing prevalence of cancer and other chronic diseases is driving the growth of the global monoclonal antibody market. These diseases led to a greater demand for biological products, which resulted in an increased demand for monoclonal antibodies. The gradual increase in genomic R & D coupled with the emergence of cutting-edge genetic platforms, such as sequencing of the next generation, has also made a significant contribution to the market. In addition, the affordability of the technology needed for research to develop mAbs has also contributed to the market. Other factors positively impacting the market are raising awareness among patients and physicians regarding applications of mAb therapy, unveiling of better products every now and then, growing adoption of therapeutic antibodies in cost-sensitive markets, and quick approval by regulatory authorities for breakthrough therapies. Going forward, swift approvals of blockbuster mAbs for different indications are further slated to up their usage. For example, popular drugs such as Herceptin, Avastin, Rituxan and Remicade, approved by the FDA for the treatment of Crohn's disease, cancer, rheumatoid arthritis, ulcerative colitis, etc., would further stimulate the market. A disadvantage of MAb-based drugs is that they are very specific in nature and have limited objectives. In fact, they simply interact with the cells and do not penetrate them. This, to some extent, has hampered the global market for monoclonal antibodies. Another difficulty related to the use of mAbs is that they must be injected, unlike small molecule drugs.

Geographical Segmentation:
Geographically, the global monoclonal antibody market can be segmented in Europe, North America, Asia-Pacific and the rest of the world. Among them, North America holds a dominant position in the market on account of the presence of well-established healthcare infrastructure, increased emphasis by the government for infection control and management, and increasing prevalence of lifestyle-related diseases. In the near future, the market will continue on its upward trajectory thanks to increased government funding for cancer research and technological development. Going forward, Asia Pacific is also predicted exhibit considerable growth owing to rising spending power of the people in the region along with increasing spend on research and development and growing patient awareness pertaining to the therapeutic use of mAbs.

Browse More Details of the report and TOC @ https://www.researchcosmos.com/reports/global-monoclonal-antibodies-market-report-industry-overview-trends-analysis-and-future-forecast/5911489

Key Players:
The main players in the monoclonal antibody market are Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen, Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and Co., Mylan NV, Daiichi Sankyo Company, Ltd., Bayer AG, Bristol Myers Squibb, Johnson & Johnson Services, Inc., Biogen Inc., Thermo Fisher Scientific, Inc., Sanofi Genzyme, F. Hoffmann-La Roche Limited and Novo Nordisk A / S.

Scope of the report:
The report offers a comprehensive analysis of the industry by providing the estimations of market potential and forecasts with utmost granularity. Along this, the factors influential in effecting the market dynamics and trends are discussed in detail at the product level. Further, the performance of the market at the regional and country-level is assessed and the prospects with high growth potential are identified and debated.
The key players in the industry are profiled providing insights on their financial performance, market position and growth strategies. Comparative analysis on prime strategical activities of the market players delineating the key developments like mergers & acquisitions, collaborations and an evaluation of the competitive environment within the industry are provided. The report also offers a broad outlook of the market along with recommendations from industry experts on the opportunities for investment activity.
What else? Apart from the syndicated report, our in-house team has an expertise and experience in designing custom reports to meet your specific research needs and assist you in making well-informed decisions.

Make an Inquiry before buying @ https://www.researchcosmos.com/inquire/global-monoclonal-antibodies-market-report-industry-overvi/5911489

Research Cosmos is a provider of standard and customized Industry research, business intelligence and consulting services across more than 100 domains in different industries of the world. We host the trending Industry reports of the world’s top-notch publishing companies, offering services to a wide range of customers from students to fortune 500 companies and discloses the hidden opportunities in every leading industry of the world.

Kevin Stewart
kevin@researchcosmos.com
Global Sales Manager
Research Cosmos
www.researchcosmos.com
+1 888 709 8757
LinkedIn - https://www.linkedin.com/company/market-research-cosmos
Twitter - https://twitter.com/researchcosmos
Google+ - https://plus.google.com/109756852849129986268
Facebook - https://www.facebook.com/researchcosmos/

This release was published on openPR.